JR

Jay Rajanikant Shah

Active Director Partner DIN 07467077
DIN 07467077 First appointment Aug 2026
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Jay Rajanikant Shah

Data last updated:

Jay Rajanikant Shah is a Partner at Galaxy Pharma Llp (since 2026).

DIN 07467077
Primary Designation Partner
First Appointment 20 Aug 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Partner20 Aug 20262026Active

Board colleagues of Jay Rajanikant Shah

NameDINCompanyDesignation
Abhijit Rajesh Pancholi09081746Galaxy Pharma LlpDesignated Partner
Prakash Raju Renukutala11903172Galaxy Pharma LlpDesignated Partner
Sameer Sunil Deshpande07687271Galaxy Pharma LlpDesignated Partner
Sunita Shailendra SinghGalaxy Pharma LlpPartner

Directorship timeline

Open interactive timeline →
Galaxy Pharma Llp
Premium access

Shareholding and investment profile for Jay Rajanikant Shah

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Jay Rajanikant Shah

Jay Rajanikant Shah currently holds 1 directorship: Galaxy Pharma Llp (Partner, since 20 Aug 2026).

Jay Rajanikant Shah was first appointed on 20 Aug 2026 as Partner at Galaxy Pharma Llp.

The current boards of Jay Rajanikant Shah's companies include Abhijit Rajesh Pancholi (Galaxy Pharma Llp), Prakash Raju Renukutala (Galaxy Pharma Llp), Sameer Sunil Deshpande (Galaxy Pharma Llp), Sunita Shailendra Singh (Galaxy Pharma Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available